Fig. 2From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritisa The proportion of disease activity at 24 weeks after the initiation of tofacitinib treatment with or without a concomitant use of MTX. b The proportion of disease activity at 24 weeks after the initiation of baricitinib treatment with or without a concomitant use of MTX. Disease activity was categorized as follows. DAS 28-ESR < 2.6 (remission), 2.6 to < 3.2 (LDA), 3.2–5.1 (MDA), > 5.1 (HDA). MTX methotrexate, LOCF last observation carried forward, ESR erythrocyte sedimentation rate, DAS disease activity score, LDA low disease activity, MDA moderate disease activity, HDA high disease activityBack to article page